This trial is active, not recruiting.

Condition metastatic pancreatic adenocarcinoma
Treatments gemcitabine, erlotinib, oxaliplatin, folinic acid, irinotecan, 5-fu
Phase phase 2
Target EGFR
Sponsor Ludwig-Maximilians - University of Munich
Collaborator Roche Pharma AG
Start date July 2012
End date July 2015
Trial size 150 participants
Trial identifier NCT01729481, 2011-005471-17


In the current study it is examined whether patients with good risk factors (age <75 years, total serum bilirubin < 1,5xULN, no history of cardiovascular diseases) treated with gemcitabine and erlotinib who developed skin rash of any grade during the first 4 weeks of treatment have a comparable outcome as patients who receive FOLFIRINOX.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model crossover assignment
Masking open label
Primary purpose treatment
Run-In-Phase during 4 weeks: Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly Thereafter Treatment in patients with RASH-positve outcome after 4 weeks.
gemcitabine Gemzar
1000 mg/m² iv weekly
erlotinib Tarceva
100mg, once per day
(Active Comparator)
Run-In-Phase during 4 weeks: Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly RASH-negative patients quit treatment with Gemcitabine + Erlotinib and continue treatment with FOLFIRINOX: Oxaliplatin 85mg/m2 Irinotecan 180 mg/m2 Folinic acid 400 mg/m2 5-FU 400 mg/m2 bolus iv 5-FU 2400 mg/m2 46-hours continous infusion
oxaliplatin Eloxatin
85mg/m², q2weeks
folinic acid Leucovorin
400 mg/m², q2weeks
irinotecan Campto
180 mg/m², q2weeks
5-fu 5-Flourouracil
400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks

Primary Outcomes

1-year Survial rate of "good-risk" patients
time frame: Follow-Up Phase (1.5 years)

Secondary Outcomes

Evalutation of overall response rate, disease control rate and progression free survival
time frame: Approximately 12 months
Evaluation of adverse events
time frame: Treatment Phase (1.5 Years)
Translational Projects
time frame: Approximately 24 months

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - Histologically (not cytologically) confirmed metastatic pancreatic adenocarcinoma (stage IV according to UICC, each T, each N, M1 according to TNM) - At least one measurable index lesion (CT or MRI) according to RECIST criteria (V 1.1) - ECOG PS 0 and 1 - Age 18-75 years - Serum bilirubin ≤1,5x ULN (a placed biliary tract stent without concurrent cholangitis is not considered a contraindication) - Availability of tumour samples (no cytologic samples) - Written informed consent by the patient for collecting blood- and tumour-samples for translational research according to study protocol - Live expectancy of at least three months - Written informed consent - Negative pregnancy test in women with childbearing potential (to be performed within 7 days prior to treatment start) - Adequate kidney-, liver- and bone-marrow function: neutrophils >= 1500/µl, platelets >= 100.000/µ, and hemoglobin >= 8g/dl, liver transaminases<= 2,5x ULN, in case of liver metastases <= 5x ULN, serum creatinine <= 1,25x ULN, creatinine clearance ≥ 30 ml/min - Legal capacity of the patient - Option for constant long-term follow-up Exclusion Criteria: - Resectable pancreatic carcinoma - Locally advanced pancreatic cancer (non-resectable tumour without distant metastasis) - Previous palliative chemotherapy for metastatic or locally advanced, non-resectable pancreatic cancer - Previous palliative radiation or chemoradiation for locally advanced, non-resectable pancreatic cancer - Radiation therapy within four weeks prior to study enrolment or radiation of indicator lesions - Adjuvant Chemotherapy or Radiochemotherapy for pancreatic cancer ≤ 6 months prior to study ernrolment - All previously occurred metastatic cancers or cured neoplasias diagnosed within the last 5 years before study enrolment - Major surgery within 2 weeks before study start - Chronic diarrhea - Known glucuronidation-deficiency (Gilbert´s syndrome) - Acute or subacute ileus or chronic inflammatory bowel disease - Preexisting polyneuropathy > Grade I according to NCI-CTCAE v.4.0 - Relevant comorbidities which might impair patient eligibility or safety for study participation like active infections, hepatic, renal or metabolic diseases - Clinically significant cardiovascular diseases within 12 months prior to study start (e.g. unstable angina pectoris, myocardial infarction, heart failure ≥ NYHA II, cardiac arrhythmias requiring treatment)

Additional Information

Official title Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances
Principal investigator Volker Heinemann, Professor
Description The study by Burris et al. 1997 revealed a superiority of gemcitabine vs. 5-FU in terms of improvement of general condition, pain symptoms and overall survival in patients with locally advanced or metastatic pancreatic cancer. Subsequently, gemcitabine was established as a standard treatment for locally advanced and metastatic pancreatic cancer. In a series of studies gemcitabine was combined with other chemotherapeutic agents or targeted therapies. For the first time, the PA.03 study showed a significant improvement of overall survival. Patients who were treated with gemcitabine plus erlotinib had a survival of 6.24 months, compared with 5.91 months for those treated with gemcitabine plus placebo (HR 0.82, 95% CI 0.69-0.99, p=0.038). The one-year-survival rate was 23% for gemcitabine plus erlotinib vs. 17% for gemcitabine plus placebo. In a subgroup analysis of the PA.03 study, patients developing a skin rash NCI CTC ≥ grade 2 had an advanced survival (one-year-survival rate 43%) vs. those with grade 1 or 0 (one-year-survival rate 16% and 9%, respectively). Later studies confirmed the correlation between skin rash and survival. While patients developing a skin rash of any grade seem to profit most from treatment with erlotinib, the prognosis for those without rash is rather dismal. In this population, survival varied between 3.3 and 4.8 months in clinical trials (Verslype et al. 2009, Boeck et al. 2010, Manzano et al. 2010). In this patients, a modification of the treatment strategy should be considered. Which kind of treatment might lead to optimal results in these patients is not yet clear. In patients with excellent general condition complying with further prerequisits (age <75 years, total serum bilirubin < 1,5xULN, no history of cardiovascular diseases) the French Prodige study-group could show a statistical superiority for the gemcitabine-free FOLFIRINOX-scheme in terms of overall survival, progression free survival and response rate compared to gemcitabine alone. However, this superiority was gained at the expense of treatment tolerability. During treatment with FOLFIRINOX a grade 3-4 neutropenia was observed in 5.4% and a grade 3-4 diarrhea in 12.7% of patients (Conroy et al. 2011). For patients who comply with the above-named criteria FOLFIRINOX is considered an established standard of care. If a comparable efficacy of gemcitabine plus erlotinib with the published FOLFIRINOX data can be seen in the selected population, this would favour, due to the worse tolerability of FOLFIRINOX, the use of gemcitabine plus erlotinib. In summary, the following selections are conducted during the study: 1. Selection due to the inclusion criteria for treatment with FOLFIRINOX provided by Conroy et al. 2. Selection due to the development of a skin rash within four weeks of treatment 3. No signs of clinical tumour progression within the run-in phase within the first four weeks of treatment Patients who do not develope a skin rash of any grade should be treated with FOLFIRINOX. The efficacy of FOLFIRINOX in rash-negative patients has not yet been investigated.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Ludwig-Maximilians - University of Munich.